James Ahern of Laidlaw

James Ahern is an investment banker, venture capitalist based in New York City.

James serves as managing partner of leading healthcare-focused investment bank Laidlaw & Company UK Ltd., and is the founder of venture capital subsidiary company, Laidlaw Venture Partners.


With healthcare professionals and technologists continuously pushing boundaries, there has always been a demand for the newest and most innovative solutions; a demand which has in recent years been focused on state-of-the-art digital platforms. Amongst the most important developments helping to revolutionize healthcare are the rapid advances in the fields of virtual reality (VR) and its cousin, augmented reality (AR).

Examples of Artificial Intelligence (AI)—the ability for computers to replicate human cognitive abilities like reasoning and learning—have been around in some form for over 50 years. Recently, however, we have seen a number of major breakthroughs in AI, due to advances in computing power, new intelligent algorithms, and access to vast quantities of data.

In recent years, healthcare companies as a whole have outperformed the broader market. Many trends in the healthcare sector such as telehealth and wearables (wearable electronic devices that send data to doctors) were advanced and accelerated due to the Covid-19 pandemic. 


Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, in Collaboration with the Vaccine and Immunotherapy Center at Massachusetts General Hospital, Announces $5.88 Million Award from the U.S. Department of Defense

The Egyptians were the first to diagnose cancer, 5,000 years ago. But their understanding of the disease was rudimentary at best, and they had no effective treatments. It wasn’t until the mid-1700s that doctors first attempted surgery on early-stage tumors. Pity the poor patients – it was almost a century before the first anesthetics. Marie Curie’s ground-breaking research led to the first use of radiotherapy in 1900. 

Lucius Partners, LLC today announced that its portfolio company, Algorithm Sciences, Inc. (Algorithm), has competed the purchase of all assets of Flowonix Medical, Inc. The transaction was a simple asset purchase; Algorithm did not acquire the liabilities or the corporate entity of Flowonix.

Scroll to Top